We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Remsima

News List

EC approves subcutaneous formulation of Remsima® europeanpharmaceuticalreview
July 30, 2020
The European Commission has granted marketing authorisation to Celltrion’s Remsima (infliximab, CT-P13) subcutaneous formulation.
Celltrion secures EC approval for Remsima SC for five more indications pharmaceutical-business-review
July 29, 2020
Celltrion Healthcare has secured approval from the European Commission (EC) for the subcutaneous (SC) formulation of autoimmune disease drug Remsima (infliximab, CT-P13) for the treatment of five more indications.
Celltrion, Lonza Sign Contract to Manufacture Remsima Drug Substance contractpharma
September 04, 2019
Lonza’s biologics facility in Singapore to cover EU and U.S. market needs.